Gene therapy to modify pulmonary host defenses

Seminars in Respiratory Infections
Jay K KollsJudd E Shellito

Abstract

Respiratory infections remain a significant public health problem and are presently the 6th leading cause of death in the United States. Antibiotic-resistant organisms are encountered increasingly in both community-acquired and nosocomial infections. Despite progress in antibiotic development, biological-response modifiers may have increasing application to augment pulmonary host defenses against either drug-resistant infections or in high-risk hosts. Toward this end, gene therapy proposes to deliver biologicals as nucleic acids rather than protein. Gene therapy has the potential advantage of targeting the biological to specific cells or tissue compartments, and a more favorable pharmacokinetic profile. Data on gene delivery and efficacy in preclinical models of pulmonary infection are presented and discussed.

Citations

Aug 2, 2002·American Journal of Respiratory Cell and Molecular Biology·Joseph M Pilewski
Mar 20, 2004·Pediatric Pulmonology. Supplement·Jay K Kolls
Jan 20, 2006·Reproduction in Domestic Animals = Zuchthygiene·J M Morrell
Dec 31, 2014·The American Journal of Tropical Medicine and Hygiene·Wai Lun Moy, Say Tat Ooi
Nov 6, 2003·The American Journal of Medicine·Thomas A RatkoKarl A Matuszewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Current Opinion in Pharmacology
J C DaviesE W Alton
Sexually Transmitted Infections
A M Lever
The Journal of Laboratory and Clinical Medicine
Judd E Shellito
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas
M I Phillips
© 2021 Meta ULC. All rights reserved